GLP-1 drugs cut sepsis risk by 37% and may strengthen bones, protect the brain, and curb addiction

Key Findings

🦴 Spine surgery patients see surprising bone healing benefits

• Patients on GLP-1 drugs who underwent major spinal deformity surgery had 29-33% lower rates of pseudoarthrosis (failed bone fusion) at multiple time points up to 3 years

• The protective effect appeared as early as 6 months and persisted throughout the study period

• These patients also had lower readmission rates and sepsis risk after their spine procedures

🧠 Brain protection extends to neurodegenerative diseases

• GLP-1 receptors are found in key brain regions including the hippocampus and frontal cortex, areas critical for memory and cognition

• These drugs activate multiple protective pathways that reduce brain inflammation, promote cell survival, and may clear toxic proteins like amyloid-beta

• Early clinical trials show promise for Alzheimer's and Parkinson's disease, with some studies reporting preserved brain glucose metabolism

🍔 Addiction research reveals appetite control goes beyond food

• GLP-1 drugs access brain receptors that control not just food cravings but other addictive behaviors

• Research suggests these medications may help treat binge eating disorders, alcohol use disorder, and other substance addictions

• The brain pathways involved overlap with those controlling pathological consumption patterns across different substances

💊 Dual-action drugs show superior liver benefits

• Meta-analysis of 1,552 patients found dual GIP/GLP-1 drugs (like Mounjaro) more effective than single GLP-1 drugs for fatty liver disease

• Dual drugs showed 28.90 times better odds of reducing liver fat compared to placebo, versus 8.23 times for single GLP-1 drugs

• All drug types significantly improved liver fibrosis reversal with 3.72 times better odds than other treatments

⚖️ Access inequality raises ethical concerns

• High costs and shortages mean patients with genuine medical needs often can't access GLP-1 drugs while wealthy individuals use them cosmetically

• Unregulated alternatives and celebrity endorsements create safety risks and spread misinformation

• Healthcare systems struggle to balance evidence-based prescribing with resource allocation

🔬 New hormone offers complementary approach

• Peptide YY (PYY), released alongside GLP-1 in the gut, suppresses appetite without directly stimulating insulin release

• Unlike GLP-1, PYY may preserve pancreatic function rather than increasing the workload on insulin-producing cells

• PYY levels increase dramatically after bariatric surgery and may explain some weight-loss-independent metabolic improvements